vs
Side-by-side financial comparison of BRINKS CO (BCO) and Dexcom (DXCM). Click either name above to swap in a different company.
BRINKS CO is the larger business by last-quarter revenue ($1.4B vs $1.3B, roughly 1.1× Dexcom). Dexcom runs the higher net margin — 21.2% vs 4.9%, a 16.3% gap on every dollar of revenue. On growth, Dexcom posted the faster year-over-year revenue change (21.6% vs 9.1%). Over the past eight quarters, Dexcom's revenue compounded faster (12.0% CAGR vs 5.6%).
The Brink's Company is an American cash handling company, headquartered in Richmond, Virginia. Its operations include cash-in-transit, ATM replenishment & maintenance, and cash management & payment services, such as vault outsourcing, money processing, intelligent safe services, and international transportation of valuables.
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.
BCO vs DXCM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $1.3B |
| Net Profit | $68.1M | $267.3M |
| Gross Margin | 27.7% | 62.9% |
| Operating Margin | 13.1% | 25.6% |
| Net Margin | 4.9% | 21.2% |
| Revenue YoY | 9.1% | 21.6% |
| Net Profit YoY | 76.9% | 153.6% |
| EPS (diluted) | $1.62 | $0.67 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.3B | ||
| Q4 25 | $1.4B | $1.3B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.2B | $1.0B | ||
| Q4 24 | $1.3B | $1.1B | ||
| Q3 24 | $1.3B | $994.2M | ||
| Q2 24 | $1.3B | $1.0B |
| Q1 26 | — | $267.3M | ||
| Q4 25 | $68.1M | $267.3M | ||
| Q3 25 | $36.3M | $283.8M | ||
| Q2 25 | $43.7M | $179.8M | ||
| Q1 25 | $51.6M | $105.4M | ||
| Q4 24 | $38.5M | $151.7M | ||
| Q3 24 | $28.9M | $134.6M | ||
| Q2 24 | $46.2M | $143.5M |
| Q1 26 | — | 62.9% | ||
| Q4 25 | 27.7% | 62.9% | ||
| Q3 25 | 25.8% | 60.5% | ||
| Q2 25 | 24.9% | 59.5% | ||
| Q1 25 | 24.6% | 56.9% | ||
| Q4 24 | 26.1% | 58.9% | ||
| Q3 24 | 25.0% | 59.7% | ||
| Q2 24 | 25.2% | 62.4% |
| Q1 26 | — | 25.6% | ||
| Q4 25 | 13.1% | 25.6% | ||
| Q3 25 | 11.4% | 20.1% | ||
| Q2 25 | 10.3% | 18.4% | ||
| Q1 25 | 9.6% | 12.9% | ||
| Q4 24 | 8.3% | 17.0% | ||
| Q3 24 | 8.9% | 15.3% | ||
| Q2 24 | 9.3% | 15.7% |
| Q1 26 | — | 21.2% | ||
| Q4 25 | 4.9% | 21.2% | ||
| Q3 25 | 2.7% | 23.5% | ||
| Q2 25 | 3.4% | 15.5% | ||
| Q1 25 | 4.1% | 10.2% | ||
| Q4 24 | 3.0% | 13.6% | ||
| Q3 24 | 2.3% | 13.5% | ||
| Q2 24 | 3.7% | 14.3% |
| Q1 26 | — | $0.67 | ||
| Q4 25 | $1.62 | $0.67 | ||
| Q3 25 | $0.86 | $0.70 | ||
| Q2 25 | $1.03 | $0.45 | ||
| Q1 25 | $1.18 | $0.27 | ||
| Q4 24 | $0.87 | $0.37 | ||
| Q3 24 | $0.65 | $0.34 | ||
| Q2 24 | $1.02 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7B | $917.7M |
| Total DebtLower is stronger | $4.0B | — |
| Stockholders' EquityBook value | $277.7M | $2.7B |
| Total Assets | $7.3B | $6.3B |
| Debt / EquityLower = less leverage | 14.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $917.7M | ||
| Q4 25 | $1.7B | $917.7M | ||
| Q3 25 | $1.3B | $1.8B | ||
| Q2 25 | $1.4B | $1.2B | ||
| Q1 25 | $1.2B | $904.9M | ||
| Q4 24 | $1.4B | $606.1M | ||
| Q3 24 | $1.2B | $621.2M | ||
| Q2 24 | $1.2B | $939.2M |
| Q1 26 | — | — | ||
| Q4 25 | $4.0B | — | ||
| Q3 25 | $3.8B | — | ||
| Q2 25 | $3.9B | — | ||
| Q1 25 | $3.7B | — | ||
| Q4 24 | $3.7B | — | ||
| Q3 24 | $3.7B | — | ||
| Q2 24 | $3.6B | — |
| Q1 26 | — | $2.7B | ||
| Q4 25 | $277.7M | $2.7B | ||
| Q3 25 | $268.5M | $2.7B | ||
| Q2 25 | $254.6M | $2.6B | ||
| Q1 25 | $205.8M | $2.3B | ||
| Q4 24 | $184.9M | $2.1B | ||
| Q3 24 | $277.1M | $2.0B | ||
| Q2 24 | $320.5M | $2.4B |
| Q1 26 | — | $6.3B | ||
| Q4 25 | $7.3B | $6.3B | ||
| Q3 25 | $7.0B | $7.5B | ||
| Q2 25 | $7.1B | $7.3B | ||
| Q1 25 | $6.6B | $6.8B | ||
| Q4 24 | $6.6B | $6.5B | ||
| Q3 24 | $6.7B | $6.4B | ||
| Q2 24 | $6.6B | $6.8B |
| Q1 26 | — | — | ||
| Q4 25 | 14.31× | — | ||
| Q3 25 | 14.05× | — | ||
| Q2 25 | 15.48× | — | ||
| Q1 25 | 18.19× | — | ||
| Q4 24 | 20.26× | — | ||
| Q3 24 | 13.39× | — | ||
| Q2 24 | 11.26× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
